MedTrace Logo

Cooperative Study of Factor VIII Inhibitors

NCT00000582 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2012-04-27

No results posted yet for this study

Summary

To test the efficacy of prothrombin complex concentrates (Factor IX) in the treatment of hemophiliac patients who had inhibitors to Factor VIII.

Conditions

Interventions

DRUG

factor ix

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Louis Aledort · Icahn School of Medicine at Mount Sinai

  • J. Edson · University of Minnesota

  • M. Eyster · Milton S. Hershey Medical Center

  • Scott Goodnight · University of Oregon Health Sciences Center

  • William Hathaway · University of Colorado Medical Center

  • Jack Lazerson · Milwaukee Children's Hospital

  • Peter Levine · Memorial hospital

  • Jeanne Lusher · Wayne State University

  • Campbell McMillan · University of North Carolina

  • Sandor Shapiro · Thomas Jefferson University

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1978-07-31
Completion
1979-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000582 on ClinicalTrials.gov